CG Oncology, Inc. Common stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CG Oncology, Inc. Common stock generated cash of -$45,679,000, which is less than the previous year. Cash used in financing activities reached the amount of $86,997,000 last year. Net change in cash is therefore -$79,877,000.
Cash Flow
| 2022 | -29.80M | -55.35M | 119.69M |
|---|---|---|---|
| 2023 | -45.67M | -121.19M | 86.99M |
CGON Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 88.14M | 53.60M |
Operating activities | ||
Net income | -48.60M | -35.44M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 17K | 15K |
Stock-based compensation expense | 1.52M | 676K |
| Deferred income tax benefit | 1.52M | 676K |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 2.01M | -18K |
Cash generated by operating activities | -45.67M | -29.80M |
Investing activities | ||
Purchases Of Investments | -517.61M | -55.33M |
Investments In Property Plant And Equipment | 0 | -14K |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -121.19M | -55.35M |
Financing activities | ||
Common Stock Issued | 0 | 166K |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | -16.29M | 0 |
Cash used in financing activities | 86.99M | 119.69M |
Net Change In Cash | -79.87M | 34.53M |
Cash at end of period | 8.26M | 88.14M |
| Data source |